Go Deep
Monopar Therapeutics Inc.
Monopar Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,169 | -32.8 | 3.70 | 0.00 | 6,864.45 |
| Oct 2026 | 20,101 | -33.2 | 3.75 | 0.00 | 6,940.66 |
| Oct 2026 | 20,187 | -32.2 | 3.68 | 0.00 | 6,818.20 |
| Oct 2026 | 20,354 | -31.5 | 3.55 | 0.00 | 6,560.90 |
| Oct 2026 | 20,209 | -32.5 | 3.67 | 0.00 | 6,776.53 |
| Oct 2026 | 20,026 | -33.7 | 3.81 | 0.00 | 7,038.22 |
| Oct 2026 | 20,151 | -32.9 | 3.71 | 0.00 | 6,843.02 |
| Oct 2026 | 20,135 | -33.0 | 3.72 | 0.00 | 6,850.89 |
Monopar Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -5,313,300.0 | -3,893,050.0 | -5,200,795.0 | -3,437,601.0 |
| EPS | -0.6 | -0.5 | — | -0.5 |
Monopar Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -13,716,894.0 | -15,586,419.0 | -8,402,196.0 | -10,515,638.0 | — |
| EPS | -1.9 | -4.1 | -3.0 | -4.2 | — |
Monopar Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 140,717,709.0 | 60,291,071.0 | 7,345,159.0 | 13,226,954.0 |
| Total Liabilities | 2,890,156.0 | 5,254,300.0 | 1,757,393.0 | 3,137,302.0 |
| Total Equity | 137,827,553.0 | 55,036,771.0 | 5,587,766.0 | 10,089,652.0 |
Owes vs Owns
Monopar Therapeutics Inc. owed $0.03 for every $1 it owned in Jun 2026, down from $0.24 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.03× | 0.02× | 0.09× | 0.24× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Monopar Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 99.8%
How it's funded — Dec 2025
Payables 1.9%Shareholders' equity 97.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 140.4 | 60.2 | 7.3 | 13.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.3 | 0.0 | 0.0 | 0.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.1 | 0.1 | 0.1 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.2 | 0.0 | 0.0 | 0.0 |
| Payables | 2.7 | 2.3 | 1.8 | 3.1 |
| Other liabilities | 0.0 | 3.0 | 0.0 | 0.0 |
| Shareholders' equity | 137.8 | 55.0 | 5.6 | 10.1 |
| Net tangible assets | 137.8 | 55.0 | 5.6 | 10.1 |
Monopar Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -12,201,291.0 | -6,404,139.0 | -7,858,293.0 | -7,228,559.0 | — |
| Investing Activities | -63,453,114.0 | -14,338,403.0 | 4,927,748.0 | -4,918,511.0 | — |
| Financing Activities | 91,574,402.0 | 59,292,257.0 | 2,027,227.0 | 32,873.0 | — |